Federal Register Notice: FDA is providing notice of a memorandum of understanding between the agency and the National Cancer Institute to establish a formal collaboration between the two agencies in order to accelerate proteomics technology development and application in clinical settings. The two intend to collaborate in areas involving proteomics such as: sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development. To view this notice, click here.